BIOCON (Biocon Ltd.): Regulatory Approval
Biocon Limited informed the exchange about a press release dated September 21, 2026 stating that Biocon’s Pertuzumab becomes the first biosimilar to secure an EMA CHMP approval recommendation under a new tailored clinical approach. The filing time in the pack is 21 Sep 08:26 and the event is labelled Regulatory Approval with a bullish bias. According to a report from Business Standard, Biocon Ltd was gaining for a third consecutive session around the same window.
The pack does not attach a Strota reaction base-rate block to this catalyst, so there is no historical win_rate or net_edge_pct to cite for the approval class here. Price markers show last 395.0 against prev_close 385.0, a change_pct of 2.6, with Nifty at +0.35 percent on the as_of date.
Nearby catalysts cut both ways. News items in the pack also note a USFDA approval for Liraglutide around 2026-09-11 to 2026-09-12, and separately a stake sale framed as a Rs 635-cr block deal in mid-September. Technicals as of last_date 2026-09-18 show the share below both the 50-day and 200-day averages, RSI14 at 36.4, rvol at 2.81, high_52w 447.15 and low_52w 337.05. Valuation markers include mcap_cr 64366.0, pe 115.25, pb 1.88, eps 3.43 and div_yield_pct 0.13. July institutional flow was large and two-sided, with MYLAN INC. selling 1839.34 crore and several mutual funds buying, led by ICICI PRUDENTIAL MUTUAL FUND at 737.5 crore. The lead fact remains the EMA CHMP recommendation on Pertuzumab under the tailored clinical approach.
The catalyst
Biocon Limited has informed the Exchange regarding a press release dated September 21, 2026, titled "Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach". (filing · NSE)
What the data shows after this event
Strota has not yet measured a reliable next-session base rate for Regulatory Approval events on enough history.
BIOCON right now
trading +2.60% on the day; P/E 115.25; RSI 36.4. Full BIOCON analysis →
Sources
- Biocon Limited has informed the Exchange regarding a press release dated September 21, 2026, titled "Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach". — NSE
- Biocon Ltd gains for third consecutive session — Business Standard
- Biocon (NSEI:BIOCON) Stock Gets Fair Value Bump As Analysts Weigh Execution And Earnings Visibility — Simply Wall St.
- Bonus + Stock Splits + Dividends + Buybacks From June 29-July 3: Bajaj, M&M, Biocon, TechM; 46 Stocks In Focus — goodreturns.in
- 3 India Pharma Exporter Stocks Facing Fresh US Tariff Pressure — Simply Wall St.
Keep digging
- BIOCON — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
- Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
- Newsroom: the other stocks in play this session.